Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Phase 2

Active, not recruiting

Conditions: Non-small-cell Lung Cancer
Advanced Malignancies

Interventions: Drug: PF-06801591

First Posted Date: 2019-11-29

Last Posted Date: 2025-02-18

Lead Sponsor: Pfizer

Target Recruit Count: 155

Registration Number: NCT04181788

Locations: 🇨🇳
Beijing Cancer hospital, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

and more 38 locations

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + Letrozole
Drug: Letrozole
Drug: Palbociclib + an aromatase inhibitor

First Posted Date: 2019-11-25

Last Posted Date: 2024-08-23

Lead Sponsor: Pfizer

Target Recruit Count: 813

Registration Number: NCT04176354

Locations: 🇺🇸
Pfizer, New York, New York, United States

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Completed

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Interventions: Drug: sunitinib

First Posted Date: 2019-11-25

Last Posted Date: 2023-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 102

Registration Number: NCT04175262

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2019-11-21

Last Posted Date: 2025-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 375

Registration Number: NCT04173273

Locations: 🇩🇪
Medius Klinik Nuertingen, Nuertingen, Germany
🇹🇷
T.C. Saglik Bakanligi Ankara Sehir Hastanesi, Ankara, Turkey
🇺🇸
Antelope Valley Eye Care - Ophthalmologist, Lancaster, California, United States

and more 515 locations

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Phase 1

Terminated

Conditions: Gastrointestinal Tumors
Colorectal Adenocarcinomas
Gastric Adenocarcinomas
Esophageal Adenocarcinomas

Interventions: Drug: PF-07062119
Drug: Anti-PD1
Drug: Anti-VEGF

First Posted Date: 2019-11-20

Last Posted Date: 2025-01-16

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT04171141

Locations: 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸
UCLA Department of Medicine: Hematology-Oncology, Los Angeles, California, United States
🇺🇸
UCLA Hematology Oncology - Santa Monica, Santa Monica, California, United States

and more 16 locations

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Non-muscle Invasive Bladder Cancer

Interventions: Drug: PF-06801591
Drug: Bacillus Calmette-Guerin

First Posted Date: 2019-11-15

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 1070

Registration Number: NCT04165317

Locations: 🇺🇸
Urological Associates of Southern Arizona, P.C ., Tucson, Arizona, United States
🇺🇸
Urological Associates of Southern Arizona P.C., Tucson, Arizona, United States
🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States

and more 175 locations

Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal

Withdrawn

Conditions: Ulcerative Colitis

First Posted Date: 2019-11-07

Last Posted Date: 2021-01-27

Lead Sponsor: Pfizer

Registration Number: NCT04156672

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Completed

Conditions: EGFR Mutation-positive Inoperable or Reccrent NSCLC

Interventions: Drug: dacomitinib hydrate

First Posted Date: 2019-11-07

Last Posted Date: 2025-05-23

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT04155541

Locations: 🇯🇵
Pfizer Japan, Tokyo, Japan

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Melanoma Cancer
Gastric Cancer
Pancreatic Cancer
Esophageal Cancer
Bile Duct Cancer
Endometrial Cancer
Renal Cell Carcinoma
Lung Squamous Cell Carcinoma
Ovarian Cancer

Interventions: Drug: PF-06940434
Drug: PF-06801591

First Posted Date: 2019-11-05

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 85

Registration Number: NCT04152018

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 28 locations

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07081532

First Posted Date: 2019-11-01

Last Posted Date: 2020-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT04148209

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy